Free Trial
NASDAQ:HLVX

HilleVax Q2 2024 Earnings Report

HilleVax logo
$2.06 +0.01 (+0.49%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$2.06 0.00 (0.00%)
As of 08/7/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax EPS Results

Actual EPS
-$0.83
Consensus EPS
-$0.73
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Friday, August 9, 2024
Conference Call Time
6:00AM ET

Upcoming Earnings

HilleVax's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 15, 2025 at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HilleVax Earnings Headlines

HilleVax Reports Second Quarter 2025 Financial Results
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat